[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Anders_Research Avatar @Anders_Research Anders Research

Anders Research posts on X about $immx, $aclx, $stim, $capr the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXX% stocks XXXX% currencies XXXX%

Social topic influence $immx #5, $aclx #9, $stim #2, $capr #12, glad #599, $qcls #12, shell #661, $ivvd #5, events 5.13%, strong XXXX%

Top accounts mentioned or mentioned by @badvalla40301 @longroaderstar @citrini7 @martinshkreli @zubicnemanja @idalopirdine @bowtiedbiotech @viewfromahill9 @andre_agtc @saicharanaitha @dnobel22 @genejchan @edwardjjiang @commonsenseplay @adamfeuerstein @macrotactical @toiletkingcap @gavmccracken @gallard70146933 @ryansttrader

Top assets mentioned Arcellx, Inc. Common Stock (ACLX) ImmunityBio, Inc. Common Stock (IBRX) Bitcoin Incognito (XBI) IonQ, Inc. (IONQ) Rigetti Computing, Inc. Common Stock (RGTI) D-Wave Quantum Inc. (QBTS) Janux Therapeutics, Inc. Common Stock (JANX) Apogee Therapeutics, Inc. Common Stock (APGE) Cidara Therapeutics, Inc. (CDTX) Prothena Corporation plc Ordinary Shares (PRTA) AstraZeneca PLC (AZN)

Top Social Posts

Top posts by engagements in the last XX hours

"Some interesting angles on $VTGN. Comparison of Q2 vs. Q3 8-K showing softer language regarding regulatory pathway is interesting. Data to date are all over the place. Still the part of my brain that has led me astray before feels like this uber-controlled trial could hit"
X Link 2025-12-03T03:55Z 3793 followers, 2454 engagements

"LOL Shkreli account completely wiped out by $CAPR Says hes sorry if anybody joined me on that He also wants you to know that: 1) Its no big deal (for him) 2) He is glad the account blew up 3) $QCLS a nano-cap quantum-adjacent shell co he is advising is the next move. 🧵"
X Link 2025-12-04T16:26Z 3793 followers, 436.5K engagements

"Says the account is no big deal started with $30k went to $260k then zero. Basically says you guys (those complaining in the chat) seem to care more about it than I do Maybe they care about heir own money (Nevermind that the $30k is completely unverifiable and he talked a lot about adding capital to cover/short more quantum etc.)"
X Link 2025-12-04T16:26Z 3793 followers, 40K engagements

"Answer to will $IMMX do a raise soon: a resounding yes. $XXX million deal already priced slightly below Friday's close (which was up XX% from the start of the week). No wonder this thing ran so hard on Thurs/Fri. Definitely no trading on NMPI"
X Link 2025-12-08T02:50Z 3793 followers, 1157 engagements

"Pretty good week going for $IVVD Did $PALI remind people that it is kind of a big deal that Point72 took an X% stake in $IVVD"
X Link 2025-10-09T19:01Z 3786 followers, 3499 engagements

"$MAIA with a rough go recently and unlikely to stop. Example of the biotech financing doom loop. Has interesting data but not quite at level where it has been able to convinced fund larger trials. Lack of catalysts begets lack of capital which begets lack of catalysts"
X Link 2025-11-19T23:03Z 3780 followers, XXX engagements

"Mid-cap value manager talking to a generalist manager last night: "And even the smaller biopharma names are interesting I've been poking around there." Nevermind that he eventually told me he is looking at $ANVS. The generalists are coming"
X Link 2025-11-21T17:31Z 3776 followers, 1208 engagements

"Interesting this Kelonia abstract is only affecting $ACLX and not $KYTX $CABA and even $IMMX. Probably because $KYTX $CABA and $IMMX are tiny and will have time to capture value. In-vivo a long-term overhang for all CAR Ts including $IMMX"
X Link 2025-11-24T19:31Z 3786 followers, 2416 engagements

"Looks like $IBRX gonna keep going up this coming week. Lots of random accounts tweeting about it all of the sudden. Maybe just my feed but feels like it is really catching on with retail. Correcting lymphopenia is easy to understand and Dr. Soon-Shiong is a good promoter"
X Link 2025-11-29T23:34Z 3786 followers, 3229 engagements

"@Citrini7 @edwardjjiang Fair enough though I would point out $XBI is up XX% over the past X months and $BBC which seems to be a closer comparator to this basket is up 91%"
X Link 2025-12-02T15:10Z 3779 followers, XXX engagements

"Was a bit nervous that we could see some worsening at X months but $GUTS OL results continue to validate Revita. If the pbo-controlled cohort performs similarly the disparity on the graph will be quite striking (placebo regained XX% at X months). Catalysts still strong"
X Link 2025-12-02T16:51Z 3782 followers, 5305 engagements

"Is there any chance that the reason all of the quantum stocks are up big the past two days is because Shkreli had to unwind his shorts due to $CAPR loss $RGTI $QBTS $IONQ all up double digits today after a big day yesterday. Probably nothing"
X Link 2025-12-04T19:11Z 3786 followers, 15.4K engagements

"@idalopirdine @MartinShkreli Yes most know what they are getting into though there were definitely a fair number of precious lambs sacrificed yesterday. Its on them lesson learned"
X Link 2025-12-04T19:40Z 3776 followers, 4728 engagements

"@adamfeuerstein Super interesting. $ACLX investors have to have known that in-vivo is eventually going to win but suppose this makes it feel more real removes some of the possible doubt. Super early data but in-vivo CAR T is super interesting---just simply so superior as a modality"
X Link 2025-11-24T18:44Z 3788 followers, XXX engagements

"ASH abstract from Kelonia Therapeutics' in-vivo BCMA CAR T that is causing $ACLX to dip XX% intraday. In-vivo CAR T assuming they come to fruition are vastly superior to current CAR Ts. No wonder J&J partnered up with Kelonia earlier this month"
X Link 2025-11-24T18:54Z 3788 followers, 6649 engagements

"@BowTiedBiotech Definitely not surprised by the negative reaction in $ACLX (though maybe the magnitude). Just interesting it wasn't hitting some of the other ex-vivo CAR T names. Still a long way to go and a lot to prove for the in-vivo CAR Ts"
X Link 2025-11-25T15:00Z 3788 followers, XXX engagements

"Citrini eating the $JANX flop after he increased it to a XX% weighting in his biotech portfolio last week (#1 holding). To be fair he laid out the risk. Just highlights how difficult biotech picking is especially if you are already spread thin"
X Link 2025-12-02T01:07Z 3790 followers, 15.4K engagements

"$TRAW Have gone long a small amount. Brief long thesis: Definitely a shitco (). Needs to raise immediately after the upcoming COVID readout due before YE. But I feel that their antiviral ratutrelvir has a good chance to beat Paxlovid on time to symptom resolution viral load/rebound or both primarily because it is being dosed for XX days vs. the standard 5-day Paxlovid course. Not even sure that will get the attention of the market but that is the core of this short-term trade idea that they flash some better-than-Paxlovid results that catch on especially given the brimming M&A environment"
X Link 2025-12-06T01:31Z 3792 followers, 1177 engagements

"$CRVS starting position today ahead of January 8-week AD results. Great data so far (especially safety). Interested to see what the longer treatment duration brings. Oral administration obviously brings huge potential"
X Link 2025-12-10T14:48Z 3792 followers, 1240 engagements

"Citrini chat been in absolute shambles since yesterday after revealing he sold long-promoted/supported micro-cap MedTech names without explanation. These people (a lot of them appear to be beginner/retail/casuals) are PISSED. 🧵 Names include $STIM $AIRS $NOTV"
X Link 2025-11-18T16:26Z 3792 followers, 139.7K engagements

"$STIM a super capital-intensive unprofitable micro-cap TMS device company has been one of Citrini's (if not the) most-covered individual name this year. First two screenshots doubling down are from Nov. 4th. Next two screenshots announcing sale are from yesterday"
X Link 2025-11-18T16:26Z 3792 followers, 10.4K engagements

"Viral illness (both acute and chronic) will be a major theme in the coming decade. People's immune system continue to get weaker and the evidence linking persistent infections to chronic diseases gets stronger. $IVVD $CDTX"
X Link 2025-11-21T20:13Z 3792 followers, 1474 engagements

"@viewfromahill9 Even $NRXP is more interesting. I kept looking at $STIM since he kept mentioning itmust have looked at it X different times each time as uninspiring as the last"
X Link 2025-11-26T05:20Z 3792 followers, XXX engagements

"$IMMX KOL presentation with Dr. Heather Landau to discuss the ASH data. Besides the impressive XX% CR many of which have sustained over XXX and XXX days Dr. Landau focusing on the fundamental advantage versus bispecifics which is: NXC-201 is a one-time treatment"
X Link 2025-12-08T02:34Z 3792 followers, 1373 engagements

"As covered when the abstract came out safety continues to be stellar and is what enables the dosing of a CAR T therapy in fragile AL amyloidosis patients. With people only now apparently becoming aware of the $IMMX story could be another solid up day tomorrow"
X Link 2025-12-08T02:36Z 3792 followers, XXX engagements

"$IMMX exiting micro-cap status"
X Link 2025-12-08T02:51Z 3793 followers, 1052 engagements

"$IMMX New piece summarizing recent events discussing competitive landscape and thinking through revenue potential and valuation"
X Link 2025-12-09T14:08Z 3792 followers, 1246 engagements

"Upshot of new $IMMX piece: AL amyloidosis is severely underserved and has 30K+ US cases; gets very little recognition/notoriety but gaining. CR rate is trending towards XX% and response are durable (besides one patient that died of unrelated causes all responses are still ongoing). Competition: BiTEs look promising but very different treatment modality; should easily coexist with NXC-201 and act as a "bridge" for many patients that are not yet ready for potential one-time treatment. In-vivo CAR Ts a potential long-term threat but will give NXC-201 at least 3-5 to operate completely unopposed."
X Link 2025-12-09T14:36Z 3793 followers, 2314 engagements

"$IMMX premarket signaling another up day coming. Stock is in the midst of a dramatic re-rating after being overlooked and ignored for a long time. Should easily reach $700+ million of peak sales versus $400M current MC ($300M EV)"
X Link 2025-12-10T14:11Z 3793 followers, 1861 engagements

"$DRTS up +13%. Presented at Sidoti today. Highlighted first patient dosed in GBM approval for a prostate trial strong enrollment in pancreatic continued strong relationship with the FDA etc. Still only $400M MC with potential to treat most solid tumor types"
X Link 2025-12-10T17:54Z 3792 followers, XXX engagements